Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence

References

• Anne P R, Machtay M, Rosenthal D I, Brizel D M, Morrison W H, Irwin D H, Chougule P B, Estopinal N C, Berson A, Curran W J, Jr. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 2007; 67: 445–452
   PubMed Web of Science ®Google Scholar
• Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 2002; 52: 739–747
   PubMed Web of Science ®Google Scholar
• Barrios L, Caballín M R, Miró R, Fuster C, Guedea F, Subias A, Egozcue J. Cytogenetic effects of radiotherapy: frequency and types of chromosome aberrations. International Journal of Radiation Oncology Biology Physics 1990; 19: 371–375
   PubMed Web of Science ®Google Scholar
• Barquinero J F, Barrios L, Caballín M R, Miró R, Ribas M, Subias A, Egozcue J. Cytogenetic análisis of lymphocytes from hospital workers occupationally exponed to low levels of ionizing radiation. Mutation Research 1993; 286: 275–279
   PubMed Web of Science ®Google Scholar
• Barquinero J F, Barrios L, Caballín M R, Miró R, Ribas M, Egozcue J. Biological dosimetry in simulated in vitro partial irradiations. International Journal of Radiation Biology 1997; 71: 435–440
   PubMed Web of Science ®Google Scholar
• Bauchinger M, Blakely WF, Darroudi F, Edwards A, Fenech M, Hayata I, Köteles GJ, Lindholm C, Lloyd DC et al. 2001. Cytogenetic analysis for radiation dose assessment. A manual. IAEA Technical Reports Series no. 405, Vienna
   Google Scholar
• Calabro-Jones P M, Aguilera J A, Ward J F, Smoluk G D, Fahey R C. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Research 1988; 48: 3634–3640
   PubMed Web of Science ®Google Scholar
• Capizzi R L, Scheffler B J, Schein P S. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993; 72: 3495–3501
   PubMedGoogle Scholar
• Cigarrán S, Barquinero J F, Barrios L, Ribas M, Egozcue J, Caballón M R. Cytogenetic analyses by fluorescence in situ hybridization (FISH) in hospital workers occupationally exposed to low levels of ionizing radiation. Radiation Research 2001; 155: 417–423
   PubMedGoogle Scholar
• De Ruyk K, Lambert B, Bacher K, Gemmel F, De Vos F, Vral A, de Ridder L, Dierckx R A, Thierens H. Biologic dosimetry of 188Re-HDD/Lipiodol versus 131I-Lipiodol therapy in patients with hepatocellular carcinoma. Journal of Nuclear Medicine 2004; 45: 612–618
   PubMedGoogle Scholar
• Dunst J, Semlin S, Pigorsch S, Muller A C, Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlentherapie und Onkologie 2000; 176: 416–421
   PubMed Web of Science ®Google Scholar
• Duran A, Barquinero J F, Caballín M R, Ribas M, Puig P, Egozcue J, Barrios L. Suitability of FISH painting techniques for the detection of partial-body irradiations for biological dosimetry. Radiation Research 2002; 157: 461–468
   PubMed Web of Science ®Google Scholar
• Durante M, Yamada S, Ando K, Furusawa Y, Kawata T, Majima H, Nakano T, Tsujii H. Measurements of the equivalent whole-body dose during radiation therapy by cytogenetic methods. Physics in Medicine and Biology 1999; 44: 1289–1298
   PubMedGoogle Scholar
• Edwards A A, Lindholm C, Darroudi F, Stephan G, Romm H, Barquinero J F, Barrios L, Caballín M R, Roy L, Whitehouse C A, Tawn E J, Moquet J, Lloyd D C, Voisin P. Review of translocations detected by FISH for retrospective biological dosimetry applications. Radiation Protection Dosimetry 2005; 113: 396–402
   PubMed Web of Science ®Google Scholar
• Finnon P, Lloyd D C, Edwards A A. Fluorescence in situ hybridization detection of chromosomal aberrations in human lymphocytes: Applicability to biological dosimetry. International Journal of Radiation Biology 1995; 68: 429–435
   PubMed Web of Science ®Google Scholar
• Gebhart E, Neubauer S, Schmitt G, Birkenhake S, Dunst J. Use of a three-color chromosome in situ suppression technique for the detection of past radiation exposure. Radiation Research 1996; 145: 47–52
   PubMedGoogle Scholar
• Guerrero-Carbajal Y C, Moquet J E, Edwards A A, Lloyd D C. The persistence of FISH translocations for retrospective biological dosimetry after stimulated whole or partial body irradiation. Radiation Protection Dosimetry 1998; 76: 159–168
   Web of Science ®Google Scholar
• Huber R, Braselmann H, Kulka U, Schumacher-Georgiadou V, Bayerl A, Molls M, Bauchinger M. Follow-up analysis of translocation and dicentric frequencies, measured by FISH-chromosome painting in breast cancer patients after partial-body radiotherapy with little bone marrow exposure. Mutation Research 1999; 446: 103–109
   PubMed Web of Science ®Google Scholar
• Inano H, Onoda M, Suzuki K, Kobayashi H, Wakabayashi K. Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation. Radiation Research 2000; 153: 68–74
   PubMed Web of Science ®Google Scholar
• Knehr S, Zitzelsberger H, Bauchinger M. FISH-based analysis of radiation-induced chromosomal aberrations using different nomenclature systems. International Journal of Radiation Biology 1998; 73: 135–141
   PubMed Web of Science ®Google Scholar
• Koukourakis M I, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunology Immunotherapy 2003; 52: 127–131
   PubMedGoogle Scholar
• Kuechler A, Dreidax M, Pigorsh S U, Liher T, Claussen U, Wendt T G, Dunst J. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlentherapie und Onkologie 2003; 179: 493–498
   PubMed Web of Science ®Google Scholar
• Lee R, Yamada S, Yamamoto N, Miyamoto T, Ando K, Durante M, Tsujii H. Chromosomal aberrations in lymphocytes of lung cancer patients treated with carbon ions. Journal of Radiation Research 2004; 45: 195–199
   PubMedGoogle Scholar
• Lindholm C, Tekkel M, Veidebaum T, Ilus T, Salomaa S. Persistence of translocations after accidental exposure to ionizing radiation. International Journal of Radiation Biology 1998; 74: 565–571
   PubMed Web of Science ®Google Scholar
• Lindholm C, Edwards A. Long-term persistence of translocations in stable lymphocytes from victims of a radiological accident. International Journal of Radiation Biology 2004; 80: 559–566
   PubMed Web of Science ®Google Scholar
• Littlefield L G, Joiner E E, Colyer S P, Sallam F, Frome E L. Concentration-dependent protection against X-ray induced chromosome aberrations in human lymphocytes by the aminothiol WR-1065. Radiation Research 1993; 133: 88–93
   PubMed Web of Science ®Google Scholar
• Manola K N, Terzoudi G I, Dardoufas C E, Malik S I, Pantelias G E. Radioprotective effect of amifostine on cells from cancer prone patients and healthy individuals studied by G2 and PCC assays. International Journal of Radiation Biology 2003; 79: 831–838
   PubMed Web of Science ®Google Scholar
• Muller I, Geinitz H, Braselmann H, Baumgartner A, Fasan A, Thamm R, Molls M, Meineke V, Zitzelsberger H. Time-course of radiation-induced chromosomal aberrations in tumor patients after radiotherapy. International Journal of Radiation Oncology Biology Physics 2005; 63: 1214–1220
   PubMed Web of Science ®Google Scholar
• Perry P, Wolff S. New Giemsa method for differential staining of sister chromatids. Nature 1974; 261: 156–158
   Web of Science ®Google Scholar
• Rao C R, Chakravarti I M. Some small sample tests of significance for a Poisson distribution. Biometrics 1956; 12: 264–282
   Web of Science ®Google Scholar
• Rades D, Fehlauer F, Bajrovic A, Nahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004; 70: 261–264
   PubMed Web of Science ®Google Scholar
• Rodriguez P, Montoro A, Barquinero J F, Caballín M R, Villaescusa I, Barrios L. Analysis of translocations in stable cells and their implications in retrospective biological dosimetry. Radiation Research 2004; 162: 31–38
   PubMed Web of Science ®Google Scholar
• Savage J RK, Simpson P. On the scoring of FISH-“painted” chromosome-type exchange aberrations. Mutation Research 1994; 307: 345–353
   PubMed Web of Science ®Google Scholar
• Sevan'kaev A V, Lloyd D C, Edwards A A, Khvostunov I K, Mikhailova G F, Golub E V, Shepel N N, Nadejina N M, Galstian I A, Nugis V Y, Barrios L, Caballín M R, Barquinero J F. A cytogenetic follow-up of some highly irradiated victims of the Chernobyl accident. Radiation Protection Dosimetry 2005; 113: 152–161
   PubMed Web of Science ®Google Scholar
• Spencer C M, Goa K L. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995; 50: 1001–1031
   Google Scholar
• Sreedevi B, Rao B S, Nagaraj H, Pal N K. Chromosome aberration analysis in radiotherapy patients and simulated partial body exposures: biological dosimetry for non-uniform exposures. Radiation Protection Dosimetry 2001; 94: 317–322
   PubMedGoogle Scholar
• Tawn E J, Whitehouse C A. Persistence of translocation frequencies in blood lymphocytes following radiotherapy: implications for retrospective radiation biodosimetry. Journal of Radiological Protection 2003; 23: 423–430
   PubMed Web of Science ®Google Scholar
• Tucker J D, Morgan W F, Awa A A, Bauchinger M, Blakey D, Cornforth M N, Littlefield L G, Natarajan A T, Shasserre C. A proposed system for scoring structural aberrations detected by chromosome painting. Cytogenetics and Cell Genetics 1995; 68: 211–221
   PubMedGoogle Scholar
• Venkatachalam P, Solomon F D, Prabhu B K, Mohankumar M N, Gajendiran N, Jeevanram R K. Estimation of dose in cancer patients treated with fractionated radiotherapy using translocation, dicentrics and micronuclei frequency in peripheral blood lymphocytes. Mutation Research 1999; 429: 1–12
   PubMed Web of Science ®Google Scholar
• Wasserman T, Mackowiak J I, Brizel D M, Oster W, Zhang J, Peeples P J, Sauer R. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology Biology Physics 2000; 48: 1035–1039
   PubMed Web of Science ®Google Scholar
• Wasserman T H, Brizel D M, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology Biology Physics 2005; 63: 985–990
   PubMed Web of Science ®Google Scholar
• Yuhas J M, Storer J B. Differential chemoprotection of normal and malignant tissues. Journal of the National Cancer Institute 1969; 42: 331–335
   PubMed Web of Science ®Google Scholar